Clinical characteristics and outcome of mucormycosis: A multi-center retrospective analysis in Saudi Arabia over 11 years.
Saudi Arabia
epidemiology
fungal
mucormycosis
zygomycete
zygomycosis
Journal
IJID regions
ISSN: 2772-7076
Titre abrégé: IJID Reg
Pays: England
ID NLM: 9918418183106676
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
26
05
2022
revised:
23
06
2022
accepted:
01
07
2022
entrez:
9
8
2022
pubmed:
10
8
2022
medline:
10
8
2022
Statut:
epublish
Résumé
Mucormycosis is a life-threatening fungal infection with variable epidemiology between countries. Limited data are available locally; we aim to describe the clinical spectrum and outcome of mucormycosis in Saudi Arabia. A retrospective multi-center study including all patients with clinical and pathological evidence of mucormycosis in 3 tertiary care centers in Saudi Arabia from January 2009 to December 2019. Thirty-three patients were identified during the study period. The mean age was 42 years. People with diabetes accounted for 48% of the patient population. The most common site of infection was cutaneous (27%), followed by isolated sinusitis (21%) and pulmonary and rhino-orbital-cerebral mucormycosis (each 18%). The most common isolated species were Our study addressed the epidemiology of mucormycosis in Saudi Arabia and showed comparable patterns of clinical and mycological aspects to worldwide reports. Further studies are needed to evaluate mucormycosis risk factors and prognosis based on the species, site of infection and therapy type.
Sections du résumé
Background
UNASSIGNED
Mucormycosis is a life-threatening fungal infection with variable epidemiology between countries. Limited data are available locally; we aim to describe the clinical spectrum and outcome of mucormycosis in Saudi Arabia.
Methods
UNASSIGNED
A retrospective multi-center study including all patients with clinical and pathological evidence of mucormycosis in 3 tertiary care centers in Saudi Arabia from January 2009 to December 2019.
Results
UNASSIGNED
Thirty-three patients were identified during the study period. The mean age was 42 years. People with diabetes accounted for 48% of the patient population. The most common site of infection was cutaneous (27%), followed by isolated sinusitis (21%) and pulmonary and rhino-orbital-cerebral mucormycosis (each 18%). The most common isolated species were
Conclusion
UNASSIGNED
Our study addressed the epidemiology of mucormycosis in Saudi Arabia and showed comparable patterns of clinical and mycological aspects to worldwide reports. Further studies are needed to evaluate mucormycosis risk factors and prognosis based on the species, site of infection and therapy type.
Identifiants
pubmed: 35941863
doi: 10.1016/j.ijregi.2022.07.004
pii: S2772-7076(22)00085-6
pmc: PMC9356215
doi:
Types de publication
Journal Article
Langues
eng
Pagination
152-156Informations de copyright
© 2022 The Author(s).
Déclaration de conflit d'intérêts
The authors have no conflict of interest to disclose.
Références
Med Mycol. 2019 Jun 1;57(4):395-402
pubmed: 30085158
Clin Infect Dis. 2020 Sep 12;71(6):1367-1376
pubmed: 31802125
Int J Infect Dis. 2021 Oct;111:267-270
pubmed: 34450284
J Fungi (Basel). 2019 Mar 21;5(1):
pubmed: 30901907
J Infect Dis. 2005 Apr 15;191(8):1350-60
pubmed: 15776383
Ann Saudi Med. 1998;18(5):428-31
pubmed: 17344718
Clin Microbiol Rev. 2000 Apr;13(2):236-301
pubmed: 10756000
Lancet Microbe. 2022 Jul;3(7):e543-e552
pubmed: 35098179
J Glob Infect Dis. 2009 Jul;1(2):131-8
pubmed: 20300403
Clin Infect Dis. 2002 Apr 1;34(7):909-17
pubmed: 11880955
N Engl J Med. 2012 Dec 6;367(23):2214-25
pubmed: 23215557
Mycoses. 2020 Oct;63(10):1060-1068
pubmed: 32485012
Med Mycol Case Rep. 2015 Dec 13;10:11-3
pubmed: 26858932
Saudi Med J. 2016 May;37(5):567-9
pubmed: 27146621
Med Mycol. 2006 Jun;44(4):335-42
pubmed: 16772227
J Infect Public Health. 2020 Nov;13(11):1774-1779
pubmed: 32891591
Clin Microbiol Infect. 2019 Jan;25(1):26-34
pubmed: 30036666
Mycologia. 2016 Sep;108(5):1028-1046
pubmed: 27738200
Clin Infect Dis. 2005 Sep 1;41(5):634-53
pubmed: 16080086
Lancet Infect Dis. 2019 Dec;19(12):e405-e421
pubmed: 31699664